Report cover image

Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 199 Pages
SKU # IRE18444011

Description

Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Global Forecast 2024-2030


The Genitourinary Drugs Market size was estimated at USD 38.30 billion in 2023 and expected to reach USD 39.83 billion in 2024, at a CAGR 4.17% to reach USD 51.01 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Genitourinary Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Genitourinary Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Genitourinary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asieris Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage



This research report categorizes the Genitourinary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Anti-infectives
Gynecological
Hormonal Therapy
Urologicals
Indication
Benign Prostatic Hyperplasia
Bladder Cancer
Cervical Cancer
Erectile Dysfunction
Hematuria
Interstitial Cystitis
Ovarian Cancer
Prostate Cancer
Renal Cancer
Sexually Transmitted Diseases
Urinary Incontinence & Overactive Bladder
Urinary Tract Infections
Drug Type
Hormonal Therapy
Impotence Agents
Urinary Antispasmodics
Urinary pH Modifiers
Uterine Relaxants
Uterine Stimulants
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Genitourinary Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Genitourinary Drugs Market?
3. What are the technology trends and regulatory frameworks in the Genitourinary Drugs Market?
4. What is the market share of the leading vendors in the Genitourinary Drugs Market?
5. Which modes and strategic moves are suitable for entering the Genitourinary Drugs Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

199 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Genitourinary Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of genitourinary disorders
5.1.1.2. Rising number of pipeline drugs
5.1.1.3. Growing concerns about urinary incontinence and impotence
5.1.2. Restraints
5.1.2.1. Availability of counterfeit and generics drugs in the market
5.1.3. Opportunities
5.1.3.1. Collaborative R&D efforts by the pharma companies
5.1.3.2. Growing investment in healthcare for improved treatments
5.1.4. Challenges
5.1.4.1. Lack of compliance to medication
5.1.4.2. Continual patent expirations
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Genitourinary Drugs Market, by Product
6.1. Introduction
6.2. Anti-infectives
6.3. Gynecological
6.4. Hormonal Therapy
6.5. Urologicals
7. Genitourinary Drugs Market, by Indication
7.1. Introduction
7.2. Benign Prostatic Hyperplasia
7.3. Bladder Cancer
7.4. Cervical Cancer
7.5. Erectile Dysfunction
7.6. Hematuria
7.7. Interstitial Cystitis
7.8. Ovarian Cancer
7.9. Prostate Cancer
7.10. Renal Cancer
7.11. Sexually Transmitted Diseases
7.12. Urinary Incontinence & Overactive Bladder
7.13. Urinary Tract Infections
8. Genitourinary Drugs Market, by Drug Type
8.1. Introduction
8.2. Hormonal Therapy
8.3. Impotence Agents
8.4. Urinary Antispasmodics
8.5. Urinary pH Modifiers
8.6. Uterine Relaxants
8.7. Uterine Stimulants
9. Americas Genitourinary Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Genitourinary Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Genitourinary Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. AbbVie Inc.
13.1.3. Asieris Pharmaceuticals
13.1.4. Astellas Pharma Inc.
13.1.5. AstraZeneca PLC
13.1.6. Bayer AG
13.1.7. Cipla Inc.
13.1.8. Eli Lilly and Company
13.1.9. F. Hoffmann-La Roche Ltd.
13.1.10. GlaxoSmithKline PLC
13.1.11. Johnson & Johnson Services, Inc.
13.1.12. Merck & Co., Inc.
13.1.13. Novartis AG
13.1.14. Pfizer, Inc.
13.1.15. Teva Pharmaceutical Industries Ltd.
13.1.16. The Bristol Myers Squibb Company
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GENITOURINARY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GENITOURINARY DRUGS MARKET DYNAMICS
FIGURE 7. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 12. GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us